Market Size
The global Klebsiella pneumoniae infections market was valued at USD 1.26 billion in 2025 and is projected to reach USD 2.86 billion by 2033, growing at a CAGR of 7.8 % during the forecast period from 2026 to 2033.
The market is witnessing significant growth driven by the rising prevalence of hospital acquired infections, increasing incidence of antimicrobial resistant bacterial strains, and growing demand for advanced infectious disease diagnostics and treatment solutions worldwide. Klebsiella pneumoniae infections are gaining increased clinical attention due to their association with severe healthcare associated infections, including pneumonia, bloodstream infections, urinary tract infections, sepsis, and ventilator associated infections. Rising hospitalization rates, expanding intensive care unit admissions, growing immunocompromised patient populations, and increasing awareness regarding infection control measures are significantly contributing to market expansion globally. In addition, the growing threat of multidrug resistant and carbapenem resistant Klebsiella pneumoniae strains is creating strong demand for innovative therapeutic and diagnostic solutions across both developed and emerging economies.
Klebsiella pneumoniae infections are caused by the pathogenic bacterium Klebsiella pneumonia, which can lead to a range of medical conditions. Klebsiella pneumonia is a type of Gram-negative bacteria that is commonly found in the environment, including soil, water, and plants. It can also inhabit the human body, particularly in the gastrointestinal tract and respiratory system.
While it is often harmless in healthy individuals, it has the potential to cause various infections, especially in people with compromised immune systems or underlying health conditions. This is because Klebsiella pneumoniae can produce a thick, sticky substance called a capsule that helps it evade the body's immune defenses.
These infections can manifest in different ways, depending on the affected body part. Klebsiella pneumoniae can cause pneumonia, a lung infection that can cause symptoms such as fever, cough, and difficulty breathing. Urinary tract infections, caused by bacteria entering the urinary tract, can cause symptoms such as painful urination, frequent urination, and lower abdominal pain. Bloodstream infections can cause fever, chills, and low blood pressure. Wound infections can cause redness, swelling, and pus formation at the site of the wound.
The severity of the infection can vary, from mild cases that can be easily treated with antibiotics to more severe cases that require hospitalization and intensive medical care. In some cases, Klebsiella pneumoniae infections can also be resistant to antibiotics, making them more difficult to treat. Therefore, it is important to seek medical attention if you suspect you may have a Klebsiella pneumoniae infection.
Furthermore, the rising prevalence of antibiotic-resistant strains of Klebsiella pneumoniae, the increasing research for the novel treatment of Klebsiella pneumoniae infections, and increasing clinical trials of drugs are the factors expected to drive the market over the forecast period.
Market Summary
| Metrics | Details |
| CAGR | Prominent Growth |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Infection Type, Drug Class, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics
Advancements in Treatment Options for Managing Klebsiella Pneumoniae Infections are Expected to Drive the Market Growth
On August 18, 2022, Springer published an article stating that Klebsiella pneumoniae is an opportunistic gram-negative pathogen that can cause various infectious diseases, including Bacteremia, urinary tract infections, liver abscesses, and pneumonia. This pathogen is becoming increasingly prevalent, and multidrug-resistant K. pneumoniae strains have been identified as a critical public health threat by the World Health Organization. The threat posed by these strains is particularly concerning because the limitations of available treatment options make it difficult to effectively combat these infections.
There are some promising treatment options available. The US FDA has approved meropenem/vaborbactam for the treatment of cUTIs, with a particular focus on K. pneumoniae infections. Ongoing clinical trials have indicated that this treatment can enhance clinical cure rates and may be better tolerated than other standard therapies. Meanwhile, ceftazidime/avibactam is another important treatment option to consider when choosing the appropriate treatment for these UTIs.
Several other newer treatment options have shown promise in combating carbapenem-resistant K. pneumoniae. Imipenem/sulbactam, plazomicin, eravacycline, cefiderocol, and aztreonam-avibactam have all been reported to be active against these resistant strains. These treatments represent an important step forward in the ongoing fight against antibiotic-resistant bacteria and may help us to better manage these infections in the future. Hence, owing to the above factors, the market is expected to drive over the forecast period.
The Rising Number of Clinical Trials Focused on Addressing Klebsiella Pneumoniae Infections is Expected to Drive Market Growth
The Phramongkutklao College of Medicine and Hospital, in collaboration with Silpakorn University, has taken on the critical task of conducting an interventional clinical trial to address the alarming mortality rate among patients infected with Carbapenem-resistant Klebsiella pneumoniae (CRKP).
This study is aimed at investigating the critical role of appropriate antibiotic therapy adjusted by pharmacokinetic/pharmacodynamic (PK/PD) considerations in determining outcomes for critically ill patients. It is a well-known fact that standard antibiotic doses might not be enough to attain the desired PK/PD targets in these cases. Therefore, this research aims to compare clinical outcomes between critically ill patients who receive antibiotics with PK/PD-adjusted doses using Monte Carlo simulation and historical critically ill patients who were treated with standard practices.
The intervention model involves dose optimization through PK/PD principles. The study is anticipated to commence in May 2023, with an estimated completion by June 2024. This initiative addresses the urgent need for more effective antibiotic treatment strategies for CRKP infections in critically ill patients, which is a pressing public health concern.
The trial is expected to provide essential insights into the potential of PK/PD-adjusted antibiotic therapy in improving clinical outcomes for critically ill patients infected with CRKP. This is a crucial step forward in the battle against antimicrobial resistance, which poses a severe threat to global public health. The findings of this study will provide valuable information to healthcare professionals and policymakers alike, guiding the development of more effective treatment protocols for CRKP infections. Hence, owing to the above factors, the market is expected to drive over the forecast period.
Rapid Prediction of Multidrug-Resistant Klebsiella Pneumoniae through Deep Learning Analysis of SERS Spectra is Expected to Drive Market Growth
Klebsiella pneumoniae is a highly concerning pathogen that poses a significant threat in clinical settings due to its potential to cause serious and difficult-to-treat infections. The pathogen's increasing multidrug resistance worldwide further exacerbates the need for rapid and accurate identification in clinical diagnosis to prevent and control infection.
However, conventional and molecular methods for diagnosis are limited and can significantly delay the timely diagnosis of the pathogen. To address this challenge, researchers conducted a study to develop a novel, label-free, noninvasive, and low-cost method for diagnosing K. pneumoniae infections. The study utilized surface-enhanced Raman scattering (SERS) spectroscopy to generate SERS spectra for 121 K. pneumoniae strains with varying drug resistance profiles, including polymyxin-resistant K. pneumoniae (PRKP), carbapenem-resistant K. pneumoniae (CRKP), and carbapenem-sensitive K. pneumoniae (CSKP).
To predict the drug resistance of K. pneumoniae strains, the SERS spectra were computationally analyzed using the convolutional neural network (CNN). The CNN model was enhanced with an attention mechanism, resulting in prediction accuracy as high as 99.46%. The model also exhibited a robustness score of 5-fold cross-validation at 98.87%.
These findings validate the accuracy and robustness of SERS spectroscopy in predicting drug resistance of K. pneumoniae strains, due to the assistance of deep learning algorithms. The study successfully discriminated against and predicted PRKP, CRKP, and CSKP strains to provide a valuable tool for clinical diagnosis. Hence, owing to the above factors, the market is expected to drive over the forecast period.
Limited Treatment Options for KPC-Producing Klebsiella pneumoniae is Expected to Hamper the Market Growth
Infections caused by Klebsiella pneumoniae can prove to be a challenge to treat, especially when they are multidrug-resistant. The slow pace of developing new antibiotics that specifically target Klebsiella pneumoniae can hinder effective treatment strategies.
The challenge is further accentuated in cases of KPC-producing Klebsiella pneumoniae, where treatment options are limited. In such cases, a microbiology laboratory must run specific tests to determine which antibiotics would be effective in treating the infection. It is recommended that patients with KPC-KP infections receive treatment with two or more drugs that display activity against the isolate. This approach has been shown to improve survival rates in such patients. Thus, owing to the above factors, the market is expected to hamper over the forecast period.
Market Geographical Share
North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Research for New Therapies For Antibiotic-Resistant Klebsiella, the Rising Clinical Trials for Drugs, Increasing Funding to Develop a New Vaccine
North America region is expected to hold the largest market share over the forecast period owing to the new therapies for antibiotic-resistant Klebsiella, the rising clinical trials for drugs, and increasing funding to develop a new vaccine.
For instance, on May 6, 2022, Evofem Biosciences, Inc. announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi (lactic acid, citric acid, and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to the general population.
Moreover, on May 18, 2023, a study was conducted by researchers from Washington University School of Medicine in collaboration with Omniose to explore the efficacy of bioconjugate vaccines for hypervirulent and drug-resistant strains of Klebsiella in mice. The study, which was published in PLoS Pathogens, aimed to enhance the immune response by connecting sugars on the surface of Klebsiella to proteins.
The research team tested two types of vaccines, one targeting the O-antigen and the other targeting the K-antigen. The capsule vaccine displayed exceptional efficacy in safeguarding mice against Klebsiella infections in the lungs and bloodstream. The study's findings have promising implications for the development of an effective vaccine against Klebsiella infections. Thus, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.
Market Companies
The major global players in the klebsiella pneumoniae infections market include Pfizer Inc., Novartis AG, AdvaCare Pharma, Merck & Co., Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Colombia, Par Pharmaceutical, AbbVie, and Actavis among others.
Key Developments
April 2026: Pfizer expanded research efforts targeting multidrug-resistant bacterial infections, including Klebsiella pneumoniae, focusing on novel anti-infective therapies and antimicrobial resistance management programs.
March 2026: Merck & Co. strengthened its infectious disease pipeline through investments in advanced antibacterial drug development and hospital-acquired infection treatment solutions targeting resistant Gram-negative pathogens.
February 2026: Shionogi & Co., Ltd. advanced clinical development programs for innovative antimicrobial therapies designed to address carbapenem-resistant Klebsiella pneumoniae and other priority bacterial infections.
January 2026: Japan increased investments in antimicrobial resistance surveillance, rapid diagnostic technologies, and infectious disease research initiatives, supporting improved detection and management of resistant bacterial pathogens.
December 2025: Roche expanded molecular diagnostic capabilities for rapid identification of drug-resistant bacterial infections, enhancing clinical decision-making and targeted treatment strategies in healthcare facilities.
November 2025: The United States strengthened funding for antimicrobial resistance research and hospital infection control programs, supporting development of new therapies and diagnostics for multidrug-resistant bacterial infections.
October 2025: bioMérieux introduced advanced diagnostic solutions for rapid detection of antimicrobial resistance markers associated with Klebsiella pneumoniae and other healthcare-associated pathogens.
September 2025: India accelerated investments in antimicrobial resistance monitoring and infectious disease management programs across major healthcare institutions, supporting improved surveillance and treatment outcomes.
July 2025: GSK expanded research collaborations focused on next-generation antibacterial therapies and innovative approaches to combat resistant Gram-negative bacterial infections globally.
May 2025: Europe strengthened antimicrobial stewardship initiatives and investments in infectious disease diagnostics across Germany, France, and the Netherlands, supporting efforts to reduce the burden of drug-resistant bacterial infections.
March 2025: Abbott enhanced its microbiology and infectious disease diagnostic portfolio with advanced testing solutions for rapid pathogen identification and antimicrobial susceptibility assessment.
January 2025: China strengthened investments in infectious disease surveillance infrastructure and antimicrobial resistance research programs, supporting improved monitoring and management of healthcare-associated bacterial infections across major healthcare centers.
Why Purchase the Report?
- To visualize the global klebsiella pneumoniae infections market segmentation based on infection type, drug class, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of klebsiella pneumoniae infections market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global klebsiella pneumoniae infections market report would provide approximately 61 tables, 61 figures, and 186 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Trending Reports:
